Targeting the ubiquitin-conjugating enzyme E2D4 for cancer drug discovery-a structure-based approach.

ABSTRACT: Cancer progression is a global burden. The incidence and mortality now reach 30 million deaths per year. Several pathways of cancer are under investigation for the discovery of effective therapeutics. The present study highlights the structural details of the ubiquitin protein 'Ubiquitin-conjugating enzyme E2D4' (UBE2D4) for the novel lead structure identification in cancer drug discovery process. The evaluation of 3D structure of UBE2D4 was carried out using homology modelling techniques. The optimized structure was validated by standard computational protocols. The active site region of the UBE2D4 was identified using computational tools like CASTp, Q-site Finder and SiteMap. The hydrophobic pocket which is responsible for binding with its natural receptor ubiquitin ligase CHIP (C-termin

SUBMITTER: Ramatenki V 

PROVIDER: S-EPMC5374094 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature